Ionis Pharmaceuticals, Inc. (IONS) Presents at Stifel 2025 Healthcare Conference Transcript

Core Insights - Ionis has had a successful year marked by significant accomplishments in commercial execution and pipeline development [3] - The company’s product TRYNGOLZA, approved in December of the previous year for FCS, has exceeded expectations, leading to revised revenue guidance for the year [4] Financial Performance - Ionis has raised its revenue guidance for TRYNGOLZA to between $85 million and $95 million for the full year, reflecting strong commercial execution [4]